Concepedia

Dmitrij Kollins

DK

Statistics

Publications

11

Citations

593

H-Index

11

Active since

2010

Affiliations

Novartis (Switzerland)(Current)

University of Leicester

Peking University

Kawasaki Medical School

Peking University First Hospital

Dmitrij Kollins is an author at Novartis (Switzerland) specializing in life sciences, immunology, and renal disease.

Publications per year

2010–2024

11

Publications

11

Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy

Vlado Perkovic, Jonathan Barratt, Brad H. Rovin et al. · New England Journal of Medicine · 2024 · 162 citations

, , +14

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

Hong Zhang, Dana V. Rizk, Vlado Perkovic et al. · Kidney International · 2023 · 121 citations · Full text

, , +17

Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study

Dana V. Rizk, Brad H. Rovin, Hong Zhang et al. · Kidney International Reports · 2023 · 60 citations · Full text

, , +15

BAMBI Regulates Angiogenesis and Endothelial Homeostasis through Modulation of Alternative TGFβ Signaling

Nicolas Guillot, Dmitrij Kollins, Victoria Gilbert et al. · PLoS ONE · 2012 · 54 citations · Full text

, , +12

BAMBI Is Expressed in Endothelial Cells and Is Regulated by Lysosomal/Autolysosomal Degradation

Sandhya Xavier, Victoria Gilbert, Maria Pia Rastaldi et al. · PLoS ONE · 2010 · 45 citations · Full text

, , +16

1–5 of 11